Treatment aimed at people who cannot be vaccinated is boost to firm’s coronavirus portfolio

AstraZeneca has received UK regulatory approval for its long-acting Covid-19 antibody treatment Evusheld in a boost to its coronavirus portfolio as the British-Swedish drugmaker targets greater drug development success at its new £1bn research lab in Cambridge.

Aimed at preventing Covid infections in people with poor immune systems who cannot be vaccinated, Evusheld is already approved in the US and other countries, and the US government has ordered 1.7m doses.

Continue reading…

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Tuesday briefing: Government may sweeten NHS England pay offer

Move from 1% to 3% still below increase sought by medics ……

Apple’s surprise OS update leaves app developers scrambling

Company releases new versions of operating systems with just a day’s notice…

Davina McCall: tide is turning on women’s health and rights

The presenter, known for her thought-provoking documentaries on women’s health, is set…

Southeastern’s state takeover will amplify calls for rail reform

Analysis: The shock is bigger than the surprise at the arrival of…